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Abstract
Background: Selenium has been shown to inhibit cancer development and growth through the mediation of
selenium-binding proteins. Decreased expression of selenium-binding protein 1 has been reported in cancers of
the prostate, stomach, colon, and lungs. No information, however, is available concerning the roles of selenium-
binding protein 1 in uterine leiomyoma.
Methods: Using Western Blot analysis and immunohistochemistry, we examined the expression of selenium-
binding protein 1 in uterine leiomyoma and normal myometrium in 20 patients who had undergone hysterectomy
for uterine leiomyoma.
Results and Discussion: The patient age ranged from 34 to 58 years with a mean of 44.3 years. Proliferative
endometrium was seen in 8 patients, secretory endometrium in 7 patients, and atrophic endometrium in 5
patients. Two patients showed solitary leiomyoma, and eighteen patients revealed 2 to 5 tumors. Tumor size
ranged from 1 to 15.5 cm with a mean of 4.3 cm. Both Western Blot analysis and immunohistochemistry showed a
significant lower level of selenium-binding protein 1 in leiomyoma than in normal myometrium. Larger tumors had
a tendency to show a lower level of selenium-binding protein 1 than smaller ones, but the difference did not
reach a statistical significance. The expression of selenium-binding protein 1 was the same among patients with
proliferative, secretory, and atrophic endometrium in either leiomyoma or normal myometrium. Also, we did not
find a difference of selenium-binding protein 1 level between patients younger than 45 years and older patients in
either leiomyoma or normal myometrium.
Conclusions: Decreased expression of selenium-binding protein 1 in uterine leiomyoma may indicate a role of the
protein in tumorigenesis. Our findings may provide a basis for future studies concerning the molecular
mechanisms of selenium-binding protein 1 in tumorigenesis as well as the possible use of selenium in prevention
and treatment of uterine leiomyoma.
Introduction
Uterine leiomyoma, the most common neoplasm of the
female genital tract, probably occurs in the majority of
women by age 50 and is responsible for significant mor-
bidity in patients [1-3]. Symptoms include pelvic pres-
sure, pelvic pain, abnormal uterine bleeding, infertility,
and miscarriage [4,5]. Uterine leiomyoma represents a
major indication for hysterectomy among women in the
United States, accounting for one-third of about 600,000
hysterectomy procedures performed annually [6,7]. Not
only is hysterectomy associated with morbidity and
mortality, but it also has a huge economic impact on
healthcare systems [1].
The scientific literature contains a large body of infor-
mation concerning the epidemiology, hormonal influ-
ence, genetics, and molecular alterations in uterine
leiomyoma. Risk factors include early menarche, nulli-
parity, obesity, African-American ethnicity, and temoxi-
fen use [8-13]. Many of these factors are associated with
increased levels of estrogen and progesterone. Estrogen
and progesterone act through the mediation of estrogen
receptor and progesterone receptor, respectively. The
majority of literature revealed higher concentrations of
estrogen and progesterone receptors in leiomyoma than
in normal myometrium [3]. Leiomyoma of the uterus
also overexpresses various growth factors including
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epidermal growth factor receptor, and platelet-derived
growth factor [3].
Inherent abnormality of myometrium in patients has
also been implicated in the development of leiomyoma
since the myometrium in the uterus harboring leio-
myoma shows a significantly higher level of estrogen
receptor than that without tumor [14]. Leiomyoma of
the uterus has been shown to be monoclonal by studies
using X-linked glucose 6-phosphate dehydrogenase iso-
zymes [15], X-linked androgen receptor [16,17], and
X-linked phosphoglycerokinase [18]. Cytogenetic studies
have identified several chromosomal alterations, includ-
ing t(12;14), del(7q), 6p21, and trisomy 12 (3). However,
it is unclear whether the genetic alterations occur before
the genesis of leiomyoma or they are secondary events.
Despite numerous studies concerning the molecular
and genetic changes in uterine leiomyoma, the mechan-
isms of development remain unknown. Further work is
needed to elucidate the pathogenesis that would lead to
the discovery of effective prevention and treatment of
the tumor.
Selenium, an essential trace element, has been shown
to have an anti-cancer effect. Many reports have
described a relationship between insufficient selenium
intake and increased risk of cancer [19-21]. The anti-
cancer action of selenium is thought to be mediated by
selenium-binding protein 1 (SELENBP1), a 56 kDa intra-
cellular protein, that binds covalently to selenium. The
gene of SELENBP1 is located at chromosome 1q21-22
[22]. The expression of SELENBP1 has been shown to
be decreased in several tumors including cancers of the
prostate, lungs, colon, and ovary [23-26]. However, little
information exists concerning the role of SELENBP1 in
tumorigenesis of uterine leiomyoma. In this study, we
examined the expression of SELENBP1 in uterine leio-
myoma and normal myometrium.
Materials and methods
T h es t u d yc o n s i s t e do f2 0c o n s e c u t i v es p e c i m e n so fh y s -
terectomy performed for leiomyoma at our institution in
July 2004. We recorded the number and size of leiomyoma
as well as the endometrial pattern in each patient. Using a
monoclonal antibody against human SELENBP1 (Medical
Biological Laboratory International Corporation, Water-
town, MA), we evaluated the expression of SELENBP1 by
Western Blot and immunohistochemistry.
For Western Blot, 100 mg sample was taken from
each leiomyoma of an unfixed uterine specimen. We
selected areas of leiomyoma without degenerative
changes. Also sampled was 100 mg of tissue from nor-
mal myometrium in the same uterus. The sample was
immediately placed in 1 ml radioimmunoprecipitation
assay buffer containing 50 mM Tris-HCl (pH7.4), 150
mM NaCl, 1% Triton X-100, 1% sodium deoxycholate,
0 . 1 %S D S ,1m MP M S F ,1m ME D T A ,5u g / m la p r o t i -
nin, 5 ug/ml leupeptin, 1 mM Na3VO4, and 5 mM NaF.
After being cut into smaller pieces with scissors, the
sample was homogenized on ice with a motor-driven
tissue Tearor for 5 times, each for 10 seconds. The
homogenate was placed on an orbital shaker at 4°C for
30 minutes and then centrifuged at 4°C with 14,000 × g
for 15 minutes. The supernatant was collected in a fresh
tube and stored at -80°C for later use.
Protein concentration was determined by a Bradford
protein assay (Bio-Rad, Hercules, CA), using bovine
serum albumin as standard. We heated each sample at
95°C for 5 minutes after mixing it with Laemmli sample
buffer containing 62.5 mM Tris-HCl (pH6.8), 20% gly-
cerol, 2% SDS, 0.01% bromophenol blue, and 5% b-mer-
captoethanol. Equal amount of protein (25 μg) from
every sample was separated on 12% sodium dodecyl sul-
fate polyacrylamide (Tris/glycine) gel and transferred to
polyvinylidene difluoride membrane. After being stained
with Ponceau S, the membrane was blocked in phos-
phate-buffered saline containing 5% nonfat dry milk for
30 minutes, and incubated with antibodies against
SELENBP1 at a dilution of 1:400 and b-actin (Santa
Cruz Biotechnology, SantaC r u z ,C A )a tad i l u t i o no f
1:200 for 1 hour. After three washes in phosphate-buf-
fered saline with 0.1% Tween 20, the membranes were
incubated with horse radish peroxidase-conjugated anti-
mouse immunoglobulin G (Medical Biological Labora-
tory International Corporation, Watertown, MA) at a
dilution of 1:10,000 for 1 hour, followed by enhanced
chemiluminescence detection (Thermo Scientific, Wal-
tham, MA) and exposure to an X-ray film. Relative
abundance of protein was determined by quantitative
densitometry using the National Institutes of Health
image program (available at http://rsb.info.nih.gov/nih-
image/). Molecular weights of proteins were determined
by extrapolation from the relative mobility of known
molecular weights. All Western Blot densitometry data
on SELENBP1 were normalized to b-actin (a house
keeping protein). The relative level of SELENBP1 was
then normalized by the mean level of SELENBP1 in nor-
mal myometrium.
To verify the result of Western Blot analysis, we per-
formed immunohistochemistry in archival tissue. Five
micron sections were taken from paraffin blocks of leio-
myoma and normal myometrium of the same uterine
specimens used for Western Blot analysis. As in Wes-
tern Blot, we selected sections of leiomyoma that did
not show degenerative changes such as infarction or
hyalinization. The sections were routinely deparaffinized
and hydrated through a gradient of ethanol. Antigen
retrieval was achieved by incubating the sections with
citrate buffer (pH 6.1) at 95°C. Sections were immersed
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block any endogenous peroxidase activity. They were
incubated with SELENBP1 antibody at a dilution of
1:200 at room temperature for 35 minutes. The sections
were then incubated with a secondary antibody pre-
viously conjugated to horseradish peroxidase-labeled
polymer at room temperature for 35 minutes. After the
sections were incubated with diaminobenzidine and
H2O2 at room temperature for 8 minutes, they were
counterstained with hematoxylin and cover-slipped.
In each run of immunohistochemistry, we included
several controls: (1) a negative reagent control (Medical
Biological Laboratory International Corporation, Water-
town, MA), used to substitute the primary antibody, (2)
a positive tissue control with a section of normal fallo-
pian tube known to be positive for SELENBP1, and (3) a
negative tissue control with a section of high-grade
ovarian serous carcinoma known to be negative for
SELENBP1. The specificity of immunostaining was con-
firmed by a positive stain in the mucosal epithelial cells
of fallopian tube but a negative stain in high-grade ovar-
ian serous carcinoma and on the sections that were
stained with a negative reagent control.
The immunostains were scored using a 4-point scale (0-
3+) system, based on the number of positive cells and the
intensity of staining; no staining was recorded as “0”,w e a k
staining in fewer than one-third of cells as “1”, moderate
staining in one-third to two-thirds of cells as “2”,a n d
strong staining in more than two-thirds of cells as “3”.
The immunostaining scores of SELENBP1 in leiomyo-
mas were correlated with vascular count on hematoxylin
and eosin stained sections of leiomyomas originating
from the same paraffin blocks used for SELENBP1
immunostain. Vascular count was defined as the num-
ber of blood vessels in 5 consecutive low power micro-
scopic fields because each section of leiomyoma
contained a minimum of 5 low power fields for evalua-
tion. To assess proliferation index relative to SELENBP1
expression, the proliferation index was determined in
sections of leiomyomas using MIB-1 antibody to the
K i 6 7a n t i g e n( D a k o ,C a r p i n t e r i a ,C A ) .W h e ne v a l u a t i n g
the results of Ki67 immunostaining, we chose the tumor
area with the highest density of positive nuclear staining.
A minimum of 200 cells on each section of leiomyoma
were analyzed. The proliferation index, represented by
the percentage of positive nuclei, was calculated by
dividing the number of positive stained cells by the total
number of cells in the areas examined. Pearson correla-
tion coefficient analysis was used to evaluate the rela-
tionship between vascular count and SELENBP1
immunostaining score as well as proliferation index and
SELENBP1 immunostaining score. When the p value
was smaller than 0.05, the relationship was considered
significant.
Wilcoxon Matched-Pair Signed-Ranks test was used to
compare the expression of SELENBP1 between leio-
myoma and normal myometrium. For cases showing
more than one leiomyoma, the average SELENBP1 level
of multiple tumors in the same patient was used to
compare with the SELENBP1 level of normal myome-
trium. In order to evaluate whether patient’sa g ew a s
related to the level of SELENBP1, we divided patients
into two arbitrary age groups: <45 years and ≥45 years.
The abundance of SELENBP1 in the two age groups
was compared with Mann-Whitney test. To determine
whether the level of SELENBP1 was related to the size
of leiomyoma, tumors were divided into four arbitrary
size groups: ≤2 cm, 2.1-5 cm, 5.1-8 cm, and ≥8c m .T h e
levels of SELENBP1 in the four size groups were com-
pared by Analysis of Variance. Analysis of Variance was
also used to compare the abundance of SELENBP1
among patients that showed proliferative, secretory, and
atrophic endometrium. The difference was considered
significant when the p value was smaller than 0.05.
Results
Patient characteristics are shown in Table 1. The patient
age ranged from 34 to 58 years, with a mean of 44.3
years. There were 8 patients with proliferative endome-
trium, 7 with secretory endometrium, and 5 with
atrophic endometrium. Two patients displayed solitary
leiomyoma, and eighteen patients showed 2 to 5 tumors.
The size of leiomyoma varied from 1 to 15.5 cm, with a
mean of 4.3 cm.
We performed Western Blot analysis on one sample of
normal myometrium and one sample of each leiomyoma
in any patient, with a total of 20 samples of normal myo-
metrium and 73 samples of leiomyoma. Western Blot
analysis using anti-human SELENBP1 recognized a single
band at 56 kDa in all samples examined. The intensity of
bands in leiomyoma was about 4-fold lower than that in
normal myometrium (examples in two patients are
s h o w ni nF i g u r e1 A ) ,a n dt h ed i f f e r e n c ew a ss t a t i s t i c a l l y
significant (Figure 1B). Although there was a trend for a
decreased expression of SELENBP1 with increasing
tumor size (Figure 2), no statistical difference was seen
among four arbitrary size groups: ≤2 cm, 2.1-5 cm, 5.1-8
cm, and ≥8 cm. The levels of SELENBP1 did not differ
between patients younger than 45 years and older
patients in either normal myometrium or leiomyoma
(Figure 3). However, the level of SELENBP1 was signifi-
cantly lower in leiomyoma than in normal myometrium
either in patients younger than 45 years or in older
patients. SELENBP1 expression did not differ among
patients with proliferative, secretory, and atrophic endo-
metrium either in normal myometrium or leiomyoma
(Figure 4), but leiomyoma showed a significantly lower
level of SELENBP1 than normal myometrium either in
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secretory endometrium, or in patients with atrophic
endometrium.
Immunohistochemistry was performed on one section
of normal myometrium and one or more sections of leio-
myoma in each case, with a total number of 20 sections
of normal myometrium and 42 sections of leiomyoma.
Normal myometrium showed diffuse and strong staining
( F i g u r e5 ) ;i nas c a l eo f0 - 3 ,t h es t a i n i n gs c o r e sr a n g e d
from 2 to 3 (mean = 2.3). The staining scores in leio-
myoma were predominantly 0 and 1 with only occasional
2 (mean = 0.8). The difference in immunostaining scores
between normal myometrium and leiomyoma was statis-
tically significant (p = 0.00357); this result confirmed the
finding by Western Blot analysis. No difference in stain-
ing was seen between patients younger than 45 years and
older patients in either normal myometrium (p = 0.3285)
or leiomyoma (p = 0.4596). The staining did not differ
among patients with proliferative, secretory, and atrophic
endometrium in either normal myometrium (p = 0.2806)
or leiomyoma (p = 0.4736). Because size of leiomyoma
was not specified for most sections used in immunohisto-
chemistry, we were not able to correlate tumor size with
immunostaining.
Among 42 available sections of leiomyomas, the vas-
cular count varied from 24 to 96 per 5 low power fields
with a mean of 38 per 5 low power fields. Statistic ana-
lysis did not reveal a significant correlation between the
vascular counts and the SELENBP1 immunostaining
scores (r = -0.0226, p = 0.4668). Proliferation index was
similar among all leiomyomas and ranged from 0 to 6%
(mean 1.2%). There was no significant correlation
between the proliferation index and the SELENBP1
immunostaining score (r = -0.1562, p = 0.2668).
Discussion
Our study showed a significant decrease of SELENBP1
in uterine leiomyoma than in normal myometrium. To
our knowledge, this is the first study to examine
SELENBP1 expression in normal myometrium and uter-
ine leiomyoma. The presence of SELENBP1 in myome-
trium indicates a normal biologic function of SELENBP1
in this tissue. SELENBP1 has been implicated to play a
role in toxification/detoxification processes [27], cell
growth regulation [28], and intra-Golgi protein transport
[29]. The decrease of SELENBP1 expression in uterine
leiomyoma suggests that SELENBP1 is related to the
development of this tumor. Although loss of SELENBP1
expression may be secondary to tumor development, the
ability of SELENBP1 to inhibit cell proliferation and
induce apoptosis in colon cancer [30] may suggest that
the protein may also be involved in tumorigenesis of
Table 1 Characteristics of patients
Case number Patient’s age (years) Endometrial pattern Number of leiomyoma Tumor size (cm)
1 43 P 1 6.5
2 50 A 4 1, 2, 3.5, 6
3 46 P 4 1.5, 2.5, 4, 7.5
44 9 S 32 , 8 , 1 2
5 34 P 5 3, 3, 4.5, 5, 15.5
6 38 S 3 1.5, 4, 6.8
7 40 S 1 5.5
8 39 P 5 1, 1.5, 2, 2, 11.8
9 36 S 4 2, 3.5, 4, 11.5
10 41 P 5 1.5, 2, 3.5, 4, 10.5
11 57 A 3 2, 5.5, 9.5
12 37 P 2 1.5, 7.5
13 45 P 5 1, 2.5, 2.5, 4, 9
14 55 A 5 2, 2, 3.5, 4, 5
15 53 A 4 1, 2, 3, 6.5
16 44 S 4 2, 2.5, 4, 5
17 58 A 4 2.5, 4, 4.5, 9
18 38 S 4 3.5, 3.5, 4, 6.3
19 42 S 4 2, 2.5, 3, 4.5
20 40 P 3 1, 3, 5.5
Mean 44.3 N/A 3.6 4.3
Abbreviations: P, proliferative; S, secretory; A, atrophic; N/A, not applicable
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and molecular events contribute to tumorigenesis, but
reduction of SELENBP1 expression may be a key step in
the transition from normal myometrium to leiomyoma.
Indeed, decreased expression of SELENBP1 in even the
smallest leiomyoma (i.e., 1 cm) examined suggests that
alteration in SELENBP1 exp r e s s i o nm a yb ea ne a r l y
event in the development of the tumor.
The mechanisms for tumorigenesis of SELENBP1 in
uterine leiomyoma are not known. The development and
growth of uterine leiomyoma has been attributed in part
to estrogen stimulation; leiomyoma enlarges during preg-
nancy when estrogen level is high and in women taking
tamoxifen or receiving estrogen-replacement therapy but
shrinks in patients with low level of estrogen after treat-
ment with gonadotropin-releasing hormone. In breast
cancer cells, selenium has been shown to disrupt estro-
gen signaling pathway by decreasing the expression of
estrogen receptors, decreasing the binding of estradiol to
estrogen receptor, inhibiting the trans-activating activity
of estrogen receptor, and reducing the binding of estro-
gen receptor to the estrogen responsive element site [31].
In myometrium showing normal expression of
SELENBP1, selenium may be able to disrupt estrogen sig-
naling pathway. When the expression of SELENBP1 is
reduced, however, leiomyoma may develop because sele-
nium without adequate SELENBP1 may be incapable of
inhibiting the stimulatory actions of estrogens.
Sex hormones change in abundance through men-
strual cycle. In women of reproductive age, estrogen
dominates in the proliferative phase, and progesterone
rises in the secretory phase. In postmenopausal women,
estrogen and progesterone levels are low. Our study
demonstrated similar levels of SELENBP1 among
patients with proliferative, secretory, and atrophic endo-
metrium in either normal myometrium or leiomyoma,
indicating that SELENBP1 is not regulated by sex hor-
mones. Also, our study did not find a difference in
SELENBP1 level between patients younger than 45 years
and older patients. In general, younger women are
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Figure 1 Western Blot analysis of SELENBP1 expression in
uterine leiomyoma and normal myometrium. (A) The bands of
SELENBP1 in two examples displayed about 4-fold lower density in
leiomyoma than in normal myometrium. (B) After normalizing for b-
actin and then for the mean of SELENBP1 in normal myometrium,
data derived from densitometry of Western Blot experiments were
used to represent relative levels of SELENBP1. Wilcoxon Signed-
Ranked test for Matched Pairs showed a significant decrease of
SELENBP1 level in leiomyoma compared to that in normal
myometrium. The vertical bars in B represent means and standard
deviations. Abbreviations: LM, leiomyoma; MM, normal myometrium;
SELENBP1, selenium-binding protein1 1; n, number of cases.
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Figure 2 Relationship between size of leiomyoma and level of
SELENBP1. After normalizing for b-actin and then for the mean of
SELENBP1 in normal myometrium, data derived from densitometry
of Western Blot experiments were used to represent relative levels
of SELENBP1. Larger leiomyomas appeared to show a lower level of
SELENBP1 than smaller ones, but no statistical difference in
SELENBP1 levels was found among the four arbitrary size groups.
The vertical bars in B represent means and standard deviations.
Abbreviations: LM, leiomyoma; MM, normal myometrium; SELENBP1,
selenium-binding protein1; n, number of leiomyomas.
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o n et h a no l d e rw o m e n .T h u st h es a m el e v e lo f
SELENBP1 regardless of age again suggests that
SELENBP1 level is not under the influence of sex
hormones.
A negative correlation between SELENBP1 expression
and Ki67 positivity has been reported in lung adenocar-
cinomas [24], but our study did not reveal a significant
relationship between SELENBP1 expression and prolif-
eration index in uterine leiomyomas. Our result may be
explained by a similarly low proliferation index among
all uterine leiomyomas examined. While no previous
report has addressed the relationship between vascular
count and SELENBP1 expression in any tumor, we
showed that vascular count was not correlated with
SELENBP1 expression in uterine leiomyomas.
Medical treatment of uterine leiomyoma involves the
use of gonadotropin-releasing hormone that inhibits ster-
oidogenesis, induces chemical menopause, and therefore
can reduce tumor volume with an improvement in clinical
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Figure 3 Expression of SELENBP1 in normal myometrium and
leiomyoma in patients younger than 45 years and older
patients. After normalizing for b-actin and then for the mean of
SELENBP1 in normal myometrium, data derived from densitometry
of Western Blot experiments were used to represent relative levels
of SELENBP1. Although the level of SELENBP1 in leiomyoma was
significantly lower than that in normal myometrium within either
<45 years group (p = 0.0004883) or within ≥45 years group (p =
0.007812), no difference in SELENBP1 level was seen between the
two age groups (p = 0.7576 in normal myometrium and p = 0.3749
in leiomyoma). The vertical bars represent means and standard
deviations. Abbreviations: LM, leiomyoma; MM, normal myometrium;
SELENBP1, selenium-binding protein1; n, number of cases.
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Figure 4 Expression of SELENBP1 in patients with different
endometrial patterns. After normalizing for b-actin and then for
the mean of SELENBP1 in normal myometrium, data derived from
densitometry of Western Blot experiments were used to represent
relative levels of SELENBP1. The level of SELENBP1 in leiomyoma
was significantly lower than that in normal myometrium in patients
with proliferative endometrium (p = 0.00782), secretory
endometrium (p = 0.01562), or atrophic endometrium (p = 0.0447);
however, no difference in SELENBP1 level was found among
patients of different endometrial patterns (p = 0.43079 in normal
myometrium and p = 0.91153 in leiomyoma). The vertical bars
represent means and standard deviations. Abbreviations: LM,
leiomyoma; MM, normal myometrium; SELENBP1, selenium-binding
protein1; n, number of cases.
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Figure 5 Immunohistochemical studies of selenium-binding
protein 1 expression. Diffuse immunostaining was seen in normal
myometrium (A), but uterine leiomyoma showed a near complete
loss of immunostain (B).
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myoma tends to grow back rapidly after cessation of ther-
apy. Lack of available effective medical therapy has made
surgery the mainstay of treatment. The complications of
surgery could be severe, particularly for young women
who wish to preserve their fertility. Therefore, searching
for novel target-based preventive and therapeutic agents
has become imperative. Selenium has been implicated as
an important chemopreventive and chemotherapeutic
agent for several epithelial tumors, including cancers of
the prostate and colon [32-34]. Our study showing a
decreased expression of SELENBP1 in uterine leiomyoma
not only indicates a role of SELENBP1 in tumorigenesis
but also suggests the potential utility of selenium in pre-
vention and treatment of uterine leiomyoma. Since the
effects of selenium are mediated by SELENBP1, loss of
SELENBP1 expression in leiomyoma may have a negative
impact on the ability of selenium to control tumor cell
growth. It has been reported, however, that treating ovar-
ian tumor cells with a selenium compound increases
SELENBP1 expression [35]. Thus the increased level of
SELENBP1 after selenium treatment may facilitate the
effect of selenium.
In summary, our study showed a decreased level of
SELENBP1 in uterine leiomyoma compared to normal
myometrium and suggested a role of SELENBP1 in
tumorigenesis of leiomyoma. Our findings may provide
a basis for future studies concerning the molecular
mechanisms of SELENBP 1 in tumorigenesis as well as
the potential use of selenium as a preventive and thera-
peutic agent in uterine leiomyoma.
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